OPK
OPKO Health·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Ample Liquidity
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About OPK
Opko Health, Inc.
A diversified healthcare company that develops a broad range of pharmaceutical products, diagnostic tests, and vaccines
4400 Biscayne Blvd., Miami, FL 33137
Build an industry-leading, fast-growing large medical market by discovering, developing and commercializing expertise and new proprietary technologies.
OPKO Health, Inc., was originally incorporated in Delaware in October 1991. The company is a diversified healthcare company seeking to establish an industry leading position in the large and rapidly growing healthcare market. The company's pharmaceutical businesses include Rayaldee, approved by the Food and Drug Administration for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and vitamin D deficiency, and Somatrogon, a weekly injection of human growth hormone, The company has partnered with Pfizer on the further development and commercialization of Somatrogon.
Earnings Call
Q1/2025
Estimate EPS-0.11
Actual EPS-0.1
Estimate Revenue164.26M
Actual Revenue149.90M
OPKO Health's Q1 2025: Unraveling Key Contradictions in NGENLA Sales and Financial Guidance
May 07,2025 02:37
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.1
Actual EPS-0.19
Estimate Revenue165.70M
Actual Revenue156.80M
OPKO Health's Q2 2025: Unpacking Contradictions in NGENLA, Diagnostics Margins, and BARDA Revenue
Jul 31,2025 09:38
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS-0.05
Actual EPS0.03
Estimate Revenue165.74M
Actual Revenue151.70M
OPKO Health's Q3 2025: Contradictions Emerge on Diagnostics Growth, Regulatory Milestones, MDX2001 Dosing, and Profitability Expectations
Oct 30,2025 01:59
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
OPK has released its 2025 Q3 earnings. EPS was reported at 0.03, versus the expected -0.05, beating expectations. The chart below visualizes how OPK has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
OPK has released its 2025 Q3 earnings report, with revenue of 151.67M, reflecting a YoY change of -12.65%, and net profit of 21.63M, showing a YoY change of -13.09%. The Sankey diagram below clearly presents OPK's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
